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ABSTRACT
Introduction: The aim of this studywas to assess
the efficacy of co-administering sitagliptin to
patients with inadequate glycemic control
following treatment with metformin (MET),
sulfonylurea (SU), or MET ? SU.
Methods: A cohort of 25,386 patients with type
2 diabetes mellitus (hemoglobin A1c
[HbA1C][53 mmol/mol or 7%), newly treated
with sitagliptin between 2007 and 2013, was
sourced from UK general practices via The
Health Improvement Network database.
Among these, eligible patients were segregated
into three groups: MET (n = 3364), SU
(n = 509), or MET ? SU therapy (n = 5929).
The relative efficacy of sitagliptin added to SU
or MET ? SU compared with sitagliptin added
to MET monotherapy was assessed with regards
to HbA1c and body weight changes from
baseline up to 52 weeks. The glycemic efficacy
was a measure of average treatment effects
obtained from multivariable linear regression
models and propensity score-matching analysis.
Results: A total of 9802patientswere included in
the study. Overall, addition of sitagliptin 100 mg
once daily resulted in 5.5 mmol/mol (0.5%)
HbA1c reduction (P\0.001) and 0.8 kg weight
reduction at 1 year (P\0.001). Efficacy was
similar across the treatment groups, but in
patients with baseline HbA1c C9% adding
sitagliptin to MET ? SU produced a significantly
smaller reduction in HbA1c when compared to
the referencegroupMET (MET? SUvs.METonly:
-0.5% vs. -0.7%, P\0.001). The mean HbA1c
reduction from baseline within this subgroup of
patients was not significantly different between
SU and MET monotherapies (-0.8% vs. -0.7%,
respectively, P = 0.4). Across treatment groups,
HbA1c reductions with add-on sitagliptin
occurred after 24 weeks of treatment with a peak
reduction occurring between 36 and 48 weeks,
and receded after week 48.
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Conclusion: In a real-world general practice
setting, sitagliptin was effective in patients
with suboptimal glycemic control with MET,
SU or dual therapy, maximum between 36 and
48 weeks, but in patients with HbA1c of[9%
receiving MET ? SU therapy, adding sitagliptin,
as a third agent, conferred minimal benefit.
Keywords: Add-on; Combination therapy;
Efficacy; Hemoglobin A1c (HBA1c);
Metformin; Sitagliptin; Sulfonylurea; Type 2
diabetes mellitus
INTRODUCTION
The majority of patients with type 2 diabetes
mellitus (T2DM) eventually require combination
therapy to control hyperglycemia as their disease
progress [1]. To this end, the use of combination
therapies from different classes that have
complementary mechanisms of action is
recommended to facilitate more effective
lowering of blood glucose levels [2]. The
combination of metformin (MET) and
sulfonylurea (SU) is the most widely used dual
combination glucose-lowering therapy (GLT) in
patients with T2DM [3]. However, combination
therapy with these two agents may also not
achieve or maintain glycemic control [4],
necessitating the need for further treatment
intensification. In this setting, use of injectable
therapy such as insulin or glucagon-like peptide 1
(GLP-1) receptor agonist is often the next
therapeutic step, although triple GLT (e.g.,
adding a thiazolidinedione to ongoing dual
therapy with MET and a SU) is also used in
clinical practice.However,manypatients find the
need for insulin injection or the adverse effects of
edema and/or an increase in body weight with
thiazolidinediones to be undesirable, which may
adversely affect treatment compliance and
glycemic response [5]. Hence, there is a need for
additional options that can be added to MET and
SU to avoid the need to switch to insulin. While
randomized clinical trials (RCT) have examined
the efficacy of various combination therapies,
comparative efficacy data from routine real-world
clinical practice could yield important and
complimentary clinical information that needs
be taken into account when determining
treatment strategies [6].
Sitagliptin is a once-a-day orally active
dipeptidyl peptidase-4 (DPP-4) inhibitor which
has been administered to improve glycemic
control in patients with T2DM treated as add-
on therapy to MET or to SU monotherapy as
well as add-on to MET-SU combination therapy
[7–9]. Real-world studies on the comparative
efficacy of the co-administration of sitagliptin
with MET, SU, or dual MET and SU therapy have
not been reported. This is relevant in view of
the fact that, although both sitagliptin and SU
stimulate insulin secretion from pancreatic
b-cells [11, 12], sitagliptin, unlike SU, also
lowers glucagon concentrations [10], which is
likely to also contribute to the glucose lowering
obtained with this agent. Although previous
RCTs have shown that sitagliptin was effective
when used as add-on combination treatment
with MET and SU therapy [9], its efficacy in real-
world practice has not been reported.
Furthermore, within this setting, if sitagliptin
is effective in combination with an SU then
triple combination therapy with MET and an SU
is likely to be effective as well.
The aim of the present work therefore is to
report the glycemic response and treatment
effect of sitagliptin when added to MET, SU, or
MET ? SU combination therapy in routine
clinical practice. To address the influence of
bias from confounders, the glycemic efficacy of
sitagliptin co-administration was evaluated
using multivariable linear regression and
propensity score-matched analysis.
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METHODS
Study Design and Data Source
Retrospective cohort analyses were conducted
of data from The Health Improvement Network
(THIN) database, which contains anonymous
patient data from more than 400 general
practices throughout England and Wales [11].
This article is based on anonymous patient data
and does not involve any new studies of human
or animal subjects performed by any of the
authors. Ethical approval was obtained as part
of the Specialist Research committee approval
by THIN, provided by the National Research
Ethics Committee South East Research Ethics
Committee.
Study Population
The study population comprised a cohort of
patients identified to have T2DM and registered
to a practice for more than 12 months before
the index date (i.e., between January 1, 2006
and the end of the study on May 30, 2013). The
cohort included patients who were C18 years
old. This consisted of patients who had
inadequate glycemic control (hemoglobin A1c
[HbA1c] levels C53 mmol/mol (7%) after
6 months of MET monotherapy, SU
monotherapy, or dual therapy consisting of
both MET and SU. Patients who were
concurrently taking other GLTs such as
thiazolidinedione, GLP-1 agonist, sodium–
glucose co-transporter-2 (SGLT-2) inhibitors,
glinides, and acarbose were excluded from the
study. In addition, patients with any records of
insulin prescription and those taking sitagliptin
as monotherapy or those taking another type of
DPP-4 inhibitor were excluded. Concurrent
lipid-lowering drugs, aspirin, and
antihypertensive medications were allowed.
Standardized computerized routines were used
to identify and extract information on patient
prescriptions for oral hypoglycemic agents
using read codes to derive the cohort that was
prescribed sitagliptin as an add-on therapy.
Exposure
Patients were administered an average of
100 mg/day of sitagliptin and the follow-up
period commenced from the index date (the
date of the first sitagliptin prescription) until a
switch to or addition of another antidiabetic
drug, or the 90th day post-index date when
HbA1c level is recorded, or 52 weeks after the
index date. Patients were segregated into the
following treatment groups based on the oral
antidiabetic treatments they received at
baseline: MET monotherapy (Group A), SU
monotherapy (Group B) and MET ? SU (Group
C). A parallel-group study involving the
underlying treatment groups was set up with
MET monotherapy group serving as the
comparison or reference group.
Outcome
The primary efficacy outcome was change from
baseline in HbA1c at 52 weeks. Secondary
outcome was change from baseline in body
weight. The glycemic efficacy of a treatment
regimen is a measure of average treatment effect
(ATE) exhibited by the treatment groups when
compared with Group A, the reference group.
Covariates
Covariates were selected a priori on the basis of
clinical significance. These are baseline
demographic and medical parameters, and
they include: age, gender, social deprivation
(measured using Townsends index scores), body
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weight, body mass index (BMI), baseline HbA1c,
total cholesterol levels, low-density lipoprotein
(LDL), high-density lipoprotein (HDL),
triglycerides, systolic and diastolic blood
pressures, smoking status, duration of DPP-4
inhibitor therapy, the use of lipid-lowering
drugs, antihypertensive drugs and aspirin, and
comorbidities (e.g., coronary heart diseases,
peripheral artery disease, cerebrovascular
disease, hypoglycemia and heart failure). In
addition, we used total duration of patients
being treated with a GLT prior to adding
sitagliptin, as a proxy of diabetes duration.
Statistical Analysis
Analysis on the primary efficacy of sitagliptin as
an add-on therapy assessed the treatment
groups for superiority with regard to the
average HbA1c change from baseline at their
respective endpoints. Multinomial propensity
scores on the baseline covariates were estimated
[12]. Balance in baseline covariates was assessed
between the treatment groups using absolute
standardized differences before and after
propensity score weighting. A standardized
effect size C20% indicated serious imbalance.
The variations in mean and frequency
distribution of measured baseline covariates
between treatment groups with the same
estimated propensity score were examined and
summarized.
Propensity Score Model
Inverse probability of treatment weighting
(IPTW) using the propensity score was
employed to estimate the measures of effect.
IPTW uses weights based on the propensity
score to create a synthetic sample in which the
distribution of measured baseline covariates is
independent of treatment status [13, 14]. The
method allowed us to estimate the ATE on the
population, enabled us ascertain how glycemic
efficacy would change if patients receiving
SU ? sitagliptin had been assigned to receive
MET ? SU before the addition of sitagliptin,
relative to whether they had all received
MET ? sitagliptin (reference group). Propensity
score was considered as a prognostic covariate
and included in the multivariable linear
regression model. Average changes in HbA1c
were calculated and expressed as point
estimates with 95% confidence interval (CI), at
the conventional statistical significance level of
0.05. Missing data in the baseline covariates was
accounted for with multiple imputations using
chained equation (MICE) model [15]. All
analyses were conducted using R [16] and
Stata [17] packages.
Secondary and Subgroup Analyses
Baseline HbA1c was categorized into four
strata: 7 to \7.5% (53–58 mmom/mol), C7.5
to \8% (58–64 mmol/mol), C8 to \9%
(64–75 mmol/mol), and C9% (75 mmol/mol).
Subgroup analysis for efficacy in endpoint
changes from baseline in HbA1c was
performed across the treatment groups. In
addition, correlation and linear regression
analysis were performed to assess the
relationship between changes in HbA1c and
changes in weight at 52 weeks in the study
population.
Bias
Our analysis employed the ‘‘new user’’ design
to minimize biases associated with prevalent
use of sitagliptins [18]. Post-index date
exposure to any GLT other than the
treatment regimen under investigation was
not permitted in our study to reduce
216 Diabetes Ther (2015) 6:213–226
confounding by indication. Patients were
segregated into separate combination
treatment groups to prevent confounding by
co-medication. In addition, propensity score
analysis was conducted to control for any
confounding differences across treatment
groups. The cohort was restricted to an
estimated 52-week follow-up to reduce the
risk of bias introduced by an overlapping
treatment effect [18]. Sensitivity analysis was
carried out to compare results of missing data
with imputed data and to assess the reliability
of the outcomes and the impact of missing
data.
RESULTS
General Patient Characteristics
Of the 25,386 users of DPP-4 inhibitor who were
screened, 9802 (39%) patients fulfilled the
criteria for cohort entry and were assigned to
one of three treatment groups as outlined in
Fig. 1. The number of patients assigned to each
treatment group includes: 3364 (34%) on
sitagliptin plus MET alone, 509 (5%) on
sitagliptin plus SU alone, and 5929 (61%) on
sitagliptin plus MET ? SU regimen. The patients
had a mean age of 62 years and were
predominantly male (60%), obese (BMI[30 kg/
m2, 62%), and on various antihypertensive
medication (73%). The average follow-up time
was 38 weeks and there was no significant
difference in baseline demographic and
metabolic characteristics of patients between
the treatment groups (Table 1).
Efficacy
Overall, the co-administration of sitagliptin to
patients who had inadequate glycemic control
from ongoing MET, SU, and MET ? SU regimen
resulted in a significant 5.5 mmol/mol (0.5%)
reduction in HbA1c (P\0.001) and a 0.8 kg
reduction in body weight (P\0.001) (Table 2).
The average HbA1c and weight reductions
across the treatment groups were generally
similar.
Propensity Score Model
The ATEs with regards to HbA1c reduction
produced by the co-administration of
sitagliptin with SU (treatment Group B) and
with MET ? SU (treatment Group C) did
not show any change in HbA1c value
(0.02% [0.2 mmol/mol], P = 0.7, and 0.03%
[0.3 mmol/mol], P = 0.2, respectively; Table 2)
However, when stratified according to levels of
HbA1c at baseline, a significant difference in the
treatment efficacy was observed in the subgroup
of HbA1c C9% at baseline (Table 2). In this
HbA1c subgroup, after adjusting for
confounders which include duration of GLT
prior to starting sitagliptin, glycemic efficacy
was significantly greater among patients in
Group A compared with their counterparts in
Group C (-0.7% vs. -0.5%, respectively,
P\0.001; Fig. 2). The mean reduction from
baseline in HbA1c was not significantly
different between the treatment Group B and
the reference Group A (-0.8% vs. -0.7%,
P = 0.4; Table 2). Hence, adding sitagliptin to
MET ? SU dual therapy (Group C) did not
confer additional glucose-lowering effects
compared with co-administration of sitagliptin
with MET nor SU monotherapies.
Overall, after adjusting for confounders, the
co-administration of sitagliptin produced a
glycemic effect that appeared to increase over
time in both treatment and reference groups.
However, this effect was not sustained
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throughout the study period, independent of all
treatment groups (Fig. 3). HbA1c reduction was
observed to take effect after 24 weeks of
treatment with sitagliptin, with a peak
reduction between week 36 and 48 and
receded after week 48. Although adding
sitagliptin to the reference Group A initially
appears to produce a better onset of effect
compared with treatment Group C (Fig. 3), our
data show that the adjusted mean changes from
baseline were not significantly different
between the treatment and reference groups.
Other Analyses
The probability density functions of the
propensity score matching of the respective
treatment groups to reference group show
there is no violation of the overlap assumption
[19] (Fig. S1 in the supplementary material), A
scatter plot of individual patient data also
shows a negative, very weak and non-
significant association between change in
HbA1c and change in weight from baseline to
endpoints. (Pearson’s correlation coefficient,
Fig. 1 Study population screening and selection process. DPP-4 dipeptidyl peptidase-4, HbA1c hemoglobin A1c, MET
metformin, SU sulfonylurea, T2DM type 2 diabetes mellitus
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Table 1 Characteristics of patients at treatment intensiﬁcation with sitagliptin
Cohort
Baseline variable MET alone (n5 3364) SU alone (n5 509) MET 1 SU (n 5 5929) ESa ESb
Demographics
Age (years), mean (SD) 61.7 (12.2) 61.5 (12.5) 61.7 (12.5) 0.01 0.00
Gender, n (%)
Male 1988 (59) 294 (58) 3516 (59) 0.03 0.00
Female 1376 (41) 215 (42) 2413 (41) 0.03 0.00
Townsend deprivation, n (%)
Least deprived 738 (22) 104 (20) 1225 (21) 0.04 0.01
Less 707 (21) 98 (19) 1247 (21) 0.04 0.00
Average 708 (21) 116 (23) 1261 (21) 0.04 0.00
More 645 (19) 104 (20) 1233 (21) 0.03 0.02
Most deprived 566 (17) 87 (17) 963 (16) 0.02 0.01
Clinical parameters, mean (SD)
HbA1c (%) 8.8 (1.4) 8.8 (1.4) 8.8 (1.4) 0.01 0.00
HbA1c category, % (mmol/mol)
7–7.5 (53–58) 610 (18) 91 (18) 1012 (17) 0.02 0.01
7.5–8 (58–64) 629 (19) 102 (20) 1133 (19) 0.03 0.01
8–9 (64–75) 1001 (30) 134 (26) 1754 (30) 0.05 0.02
C9 (75) 1124 (33) 182 (36) 2030 (34) 0.01 0.01
BMI (kg/m2) 32.8 (6.8) 32.5 (6.9) 32.6 (6.6) 0.05 0.01
Weight (kg) 93.9 (21.6) 92.8 (21.5) 93.3 (21.1) 0.05 0.01
SBP (mmHg) 134 (15.1) 133.5 (15.2) 134.5 (15.1) 0.05 0.00
DBP (mmHg) 77.4 (9.4) 76.7 (9.1) 77.2 (9.5) 0.08 0.01
TC (mmol/L) 4.3 (1.1) 4.3 (1.1) 4.3 (1.1) 0.02 0.01
HDL (mmol/L) 1.1 (0.3) 1.1 (0.3) 1.1 (0.3) 0.02 0.01
LDL (mmol/L) 2.3 (0.9) 2.3 (0.9) 2.2 (0.9) 0.01 0.00
Triglyceride (mmol/L) 2.2 (2.6) 2.2 (1.8) 2.1 (1.7) 0.02 0.02
GLT duration (years) 1.6 (2.7) 1.6 (2.7) 1.6 (2.7) 0.06 0.00
Smoking status, n (%)
Non-smoker 1333 (40) 195 (38) 2379 (40) 0.01 0.01
Current smoker 494 (15) 76 (15) 859 (14) 0.01 0.01
Ex-smoker 1537 (46) 238 (47) 2691 (45) 0.01 0.01
BMI category, n (%)
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r = -0.01; P = 0.3; Fig. 4) Therefore, the
changes in HbA1c observed in the population
do not account for the variation in weight
change. The sensitivity analysis after multiple
imputation showed similar results to our
complete case models which indicate findings
are unlikely attributable to bias from missing
information (Table S1 in the supplementary
material).
DISCUSSION
Comparative effectiveness studies which
examine the efficacy of the co-administration
Table 1 continued
Cohort
Baseline variable MET alone (n5 3364) SU alone (n5 509) MET 1 SU (n 5 5929) ESa ESb
Normal 289 (9) 47 (9) 556 (9) 0.01 0.01
Overweight 985 (29) 161 (32) 1690 (29) 0.08 0.01
Obese 2090 (62) 301 (59) 3683 (62) 0.03 0.00
Use of medications, n (%)
Aspirin 1306 (39) 208 (41) 2361 (40) 0.02 0.01
Antihypertensive 2482 (74) 363 (71) 4332 (73) 0.06 0.00
LLT 2636 (78) 394 (77) 4658 (79) 0.05 0.01
Comorbidities, n (%)
CHD 1936 (58) 293 (58) 3392 (57) 0.04 0.02
PAD 536 (16) 85 (17) 940 (16) 0.06 0.02
Cerebrovascular 767 (23) 126 (25) 1340 (23) 0.02 0.00
Heart failure 350 (10) 56 (11) 679 (11) 0.00 0.01
Hypoglycemia 667 (20) 105 (21) 1130 (19) 0.02 0.00
Follow-up (weeks)
0–12 383 (11) 51 (10) 676 (11) 0.05 0.02
12–24 370 (11) 49 (10) 644 (11) 0.02 0.00
24–36 339 (10) 48 (9) 593 (10) 0.02 0.00
36–48 826 (25) 140 (28) 1502 (25) 0.04 0.00
48–52 1446 (43) 221 (43) 2514 (42) 0.07 0.01
GLT duration is the duration of treatment from ﬁrst GLT
ES is the absolute standardized mean difference of means or percentages divided by the standard deviation
BMI body mass index, CHD coronary heart disease, DBP diastolic blood pressure, ES effect size, GLT glucose-lowering
therapy, HbA1c hemoglobin A1c, HDL high-density lipoprotein, LDL low-density lipoprotein, LLT lipid-lowering therapy,
MET metformin, PAD peripheral arterial disease, SBP systolic blood pressure, SD standard deviation, SU sulfonylurea, TC
total cholesterol
a ES in unweighted
b ES in propensity score-weighted cohort based on average treatment effect in the population
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of sitagliptin to SU or MET ? SU are not widely
reported. Even where RCTs were carried out, the
lack of rigorous patient inclusion and exclusion
criteria such as what we have explored in this
study may limit the generalizability of study
findings. Overall, this study showed the
addition of 100 mg/day of sitagliptin to
patients with T2DM with inadequate glycemic
control following MET monotherapy, SU
monotherapy or both, resulted in a
5.5 mmol/mol (0.5%) reduction in HbA1c and
a 0.8 kg weight loss at endpoint. The average
HbA1c and weight reductions across the
treatment groups were generally similar except
within a subgroup of patients who had
HbA1c C9% at baseline, where the
co-administration of sitagliptin with MET ? SU
did not confer additional significant glucose
lowering, even after adjusting for a proxy of
diabetes duration. Thus, adding sitagliptin to
SU confers equivalent benefit in Hba1c lowering
compared with adding to MET, but the use of
sitagliptin in combination with SU and MET
therapy is not efficacious. Since the glycemic
efficacy of sitagliptin co-administration was
analyzed using multivariable linear regression,
absolute comparison between treatment groups
could not be performed.
Interestingly, the latter finding contradicts
findings from a RCT, which showed additional
HbA1c reduction with sitagliptin when added to
MET plus glimepiride therapy [9]. This
Table 2 ATE of adding sitagliptin to ongoing SU monotherapy or MET plus SU dual therapy
Estimated treatment difference (95% CI)
Variables MET (reference) P value SU vs. MET P value MET 1 SU vs. MET P value
HbA1c changea
% -0.49 (-0.53, -0.45) \0.001 -0.03 (-0.14, 0.09) 0.6 0.03 (-0.02, 0.08) 0.3
mmol/mol -5.4 (-5.8, -4.9) -0.3 (-1.3, 1.0) 0.3 (0.2, 0.9)
HbA1c subgroupb
7–7.5% -0.33 (-0.44, -0.22) \0.001 0.05 (-0.21, 0.31) 0.7 0.03 (-0.08, 0.15) 0.6
53–58 mmol/mol -3.6 (-4.8, 2.4) 0.6 (-2.5, 3.7) 0.3 (-1.0, 1.8)
7.5–8% -0.37 (-0.46, -0.27) \0.001 -0.05 (-0.30, 0.19) 0.7 -0.01 (-0.12, 0.11) 0.9
58–64 mmol/mol -4.0 (-5.0, -3.0) -0.6 (-3.6, 2.3) -0.1 (-1.4, 1.3)
8–9% -0.46 (-0.53, -0.38) \0.001 -0.01 (-0.22, 0.20) 0.9 -0.02 (-0.11, 0.07) 0.6
64–75 mmol/mol -5.0 (-5.8, -4.2) -0.1 (-2.6, 2.4) -0.2 (-1.3, 0.8)
C9% -0.68 (-0.77, -0.59) \0.001 0.08 (-0.11, 0.26) 0.4 0.18 (0.16, 0.31) 0.01
C75 mmol/mol -7.4 (-8.4, -6.4) 1.0 (-1.3, 3.1) 2.2 (1.9, 3.7)
ATE 0.02 (-0.09, 0.12) 0.7 0.03 (-0.02, 0.08) 0.2
Mean (SD) PS -0.01 (1.2) 0.03 (1.2)
Weight change, kg -0.93 (-1.09, -0.78) \0.001 0.14 (-0.28, 0.56) 0.5 0.14 (-0.05, 0.33) 0.2
ATE average treatment effect in the population, BMI body mass index, CI conﬁdence interval, HbA1c hemoglobin A1c,
MET metformin, PS propensity score, SD standard deviation, SU sulfonylurea
a Change in HbA1c from PS-weighted linear regression model
b Least square mean difference from PS-weighted linear regression model
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discrepancy may reflect the longer disease
duration and diabetes progression, before
patients in real-world practice are being offered
a third-line therapy to manage their
hyperglycemia. Based on the availabilities of
other injectable therapies such as insulin or
Fig. 2 Changes in HbA1c at 52 weeks from baseline HbA1c categories. HbA1c hemoglobin A1c,MET metformin, NS not
signiﬁcant, SU sulfonylurea
Fig. 3 Changes in HbA1c at various endpoints during the 52-week follow-up. HbA1c hemoglobin A1c, MET metformin,
SU sulfonylurea
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GLP-1 analog, we would question the merit of
using sitagliptin to manage hyperglycemia as a
triple oral therapy in routine practice. However,
the observed equal benefit in HbA1c reduction
when sitagliptin was added to patients who have
failed SU therapy (compared with MET–
sitagliptin combination therapy) implies an
additional mechanism of action of sitagliptin
therapy, above and beyond its ability to
stimulate insulin secretion from an already
exhausted pancreatic b-cells, such as GLP-1 and
glucose-dependent insulinotropic peptide (GIP)-
induced suppression glucagon secretion [10].
However, results obtained from previous
systematic reviews and meta-analysis of RCTs
studies compared sitagliptin ?MET with MET
alone reported that the dual therapy effectively
improved HbA1c levels [20]. Similarly, evidence
from recent studies [21, 22] have shown that,
compared with MET monotherapy, DPP-4
inhibitor plus MET was associated with more
reduction in HbA1c level [21]. The synergistic
effect of sitagliptin withMET is increasingly well
recognized andmay be explained by the fact that
MET enhances the expression and production of
GLP-1 from the terminal ileum [23].
Another important and novel observation
from this study relates to the durability of
sitagliptin therapy. As a whole, across the
treatment group, HbA1c reduction was
observed to take effect after 24 weeks of
treatment with sitagliptin, with a peak
reduction between week 36 and 48 and
receded after week 48. This is in contrast to
most findings from RCT, where peak HbA1c
reduction seemed to occur earlier, at
approximately 6 weeks post-initiation of
sitagliptin. However, most RCTs investigating
the efficacy of DPP-4 inhibitors with SU or MET
have reported outcomes for 24 weeks. However,
one study using saxagliptin in combination
with glyburide followed up patients for
76 weeks [24]. In this study, HbA1c reduction
occurred immediately upon initiation of
saxagliptin, peak reduction after 8–12 weeks,
with a further rise in Hba1c thereafter,
returning to baseline at 76 weeks, which may
reflect the progressive nature of diabetes.
However, in the two longest-running trials of
DPP-4 inhibitors, the ‘escape phenomenon’,
assessed by a secondary increase in HbA1c
levels between weeks 24 and 104 following a
Fig. 4 Relationship between changes in HbA1c and body weight. HbA1c hemoglobin A1c
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good initial HbA1c reduction, was significantly
less pronounced with sitagliptin 100 mg or
vildagliptin 100 mg than with glipizide or
glimepiride, respectively [25, 26], suggesting
better b-cell protection and durability of
glucose control with a DPP-4 inhibitor. A more
recent 52-week RCT comparing sitagliptin
versus canagliflozin when added to MET ? SU
showed maximum HbA1c reduction at 12 weeks
and a progressive rise in Hba1c thereafter [27].
Our analyses were subjected to some
limitations inherent to observational studies;
our exposure data relate to prescriptions so we
cannot be certain that the patients were
completely compliant with their medication.
However, should there be any overestimation of
exposure to the medications in our analysis,
such a misclassification would be non-
differential and only bias results towards
unity. Although we could not account for
potential residual confounders such as
compliance, diabetes duration, indications for
different drug treatments, markers of b-cells
deterioration and differences in dosages, we
were able to account for differences in the
observed covariates and used robust analytical
techniques to control confounding that may
bias the results of the estimated treatment
effects. This included using a proxy for
diabetes duration. In addition, HbA1c level at
time of intensification (which is the same across
treatment groups) and duration of therapy since
starting MET were used as surrogate of diabetes
duration, and included in the model for
analysis.
CONCLUSIONS
In summary, the addition of sitagliptin to MET
monotherapy, SU monotherapy, and MET ? SU
regimens in patients with inadequate glycemic
control is a good therapeutic option for
achieving efficacy in patients with T2DM.
However, adding sitagliptin to an ongoing
MET ? SU regimen appears to be less
efficacious among patients whose HbA1c is
above 9% at the time of administration. We
suggest that treatment should be characterized
on an individual basis and robust RCTs are
required to fully investigate the influence of
obesity and longer treatment durations on the
efficacy of co-administering sitagliptin to
patients unresponsive to oral GLT.
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